"He went through six operations and was placed on a clinical trial so he could try new treatments.”
A trial looking at using bevacizumab for grade 2 or 3 gliomas that have come back (The TAVAREC Trial)
More about this trial
- temozolomide and bevacizumab
- temozolomide only
Summary of results
- 77 were to have temozolomide
- 78 were to have temozolomide and bevacizumab
The trial team looked at the number of people who were alive 1 year after treatment.
Of the 77 people who were to have temozolomide the team were able to look at 72 people. Of these 72 people, 44 (61%) were alive 1 year after treatment.
Of the 78 people who were to have temozolomide and bevacizumab the team were able to look at 69 people. Of these 69 people, 38 (55%) were alive 1 year after treatment.
- just under 15 months (14.8) for those who had temozolomide
- just under 13 months (12.9) for those who had temozolomide and bevacizumab
- a drop in blood cells
- feeling or being sick
How to join a clinical trial
Dr Sara Erridge
European Organisation for Research and Treatment of Cancer (EORTC)
Experimental Cancer Medicine Centre (ECMC)
F.Hoffmann-La Roche Ltd (Roche)
NIHR Clinical Research Network: Cancer